CA2211671A1 - Solid active ingredient compositions containing hydroxypropylcellulose - Google Patents
Solid active ingredient compositions containing hydroxypropylcelluloseInfo
- Publication number
- CA2211671A1 CA2211671A1 CA002211671A CA2211671A CA2211671A1 CA 2211671 A1 CA2211671 A1 CA 2211671A1 CA 002211671 A CA002211671 A CA 002211671A CA 2211671 A CA2211671 A CA 2211671A CA 2211671 A1 CA2211671 A1 CA 2211671A1
- Authority
- CA
- Canada
- Prior art keywords
- active ingredient
- hydroxypropylcellulose
- melt
- compositions
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Preparations containing active agents obtainable by the melt extrusion of A) a water-soluble thermoplastic hydroxypropyl cellulose, B) one or more active agents, C) if desired, pharmaceutical auxiliaries, in which the proportion of A) is 10 to 30 % wt. in relation to the entire preparation.
Description
Solid active ingredient compositions containing hydroxypropyl-cellulose 5 The present invention relates to solid active ingredient-contain-ing compositions obtainable by melt extrusion of a mixture of A) a water-soluble thermoplastic hydroxypropylcellulose, 10 B) one or more active ingredients and C) if required conventional pharmaceutical ancillary substances, 15 where the content of A) is from 10 to 30% of the total weight of the mixture.
The invention furthermore relates to a process for producing com-positions of this type and to drug forms from these compositions.
20 Melt extrusion and its use in pharmaceutical technology is gener-ally known.
US-A 4 801 460 describes the production of solid drug forms by melt extrusion of mixtures of active ingredient and thermoplastic 25 N-vinylpyrrolidone polymers.
JP-A 58-79915 and JP-A 58-192817 disclose the production of rod-shaped drug forms by melt extrusion of water-soluble polymers such as hydroxypropylcellulose (HPC) or mixtures of HPC with 30 other polymers.
EP-A 596 203 describes active ingredient-containing compositions which are obtained by mixing the active ingredient with a water-soluble melt of two polymers which differ in viscosity, for exam-35 ple polymer mixtures of hydroxypropylcellulose and hydroxypropyl-methylcellulose.
Active ingredient compositions disclosed to date usually have relatively high polymer contents. Although high polymer contents 40 result in good processability, the lower active ingredient con-tents which inevitably result therefrom, that is to say a low dose of active ingredient with a high tablet weight, may make the entire production process uneconomic.
45 If, for example, the active ingredient content in a tablet is originally 40% by weight, for the same dosage the tablet weight could be halved when the active ingredient content is doubled.
Thus, for a given extruder melt output, the production capacity of the extruder could be doubled.
On the other hand, in the case of active ingredients requiring a 5 low dose, a high active ingredient content would lead to drug forms whose total weight would be so low that it would be diffi-cult to handle such a small drug form. However, in such cases, it would be just as worthwhile to limit the content of the rela-tively high-cost polymers. In order for the weight of the drug 10 forms not to be less than the reasonable minimum, it would be worthwhile to replace part of the more costly polymer component by low-cost, not necessarily meltable ancillary substances.
It is an object of the present invention to find compositions 15 which have a low polymer content while permitting melt processing of the composition so that the content of active ingredient or active ingredient and low-cost ancillary substances in the com-position can be at a maximum.
20 We have found that this object is achieved by the compositions defined at the outset, and by a process for producing them, and the use thereof.
The component A) used according to the invention is a water-solu-25 ble thermoplastic hydroxypropylcellulose which preferably has a molar degree of substitution of from 3.0 to 4.4. "Molar degree of substitution" refers to the average number of moles of propylene oxide which have reacted per glucose unit in the cellulose.
30 The hydroxypropylcellulose can have melt viscosities measured by the DIN 53735 method in the range from 0.075 to 54.8 g/10 min.
The molecular weight of the hydroxypropylcellulose can vary with-in wide limits depending on whether slower or faster release of 35 active ingredient is desired. Hydroxypropylcellulose with molecu-lar weights in the range from 200,000 to 1,500,000 is suitable in particular for producing drug forms in which 510w release of act-ive ingredients is desired, since the polymers of higher molecu-lar weight dissolve less well, and only with swelling, in water.
If, however, it is intended to produce drug forms with faster release of active ingredient, it is advisable to use polymers of lower molecular weight which are readily soluble in water, it be-ing possible in this case to use hydroxypropylcellulose with a 45 molecular weight of from 60,000 to 200,000, preferably 60,000 to 100, 000.
The preparation of the hydroxypropylcellulose used according to the invention is generally known.
The content of hydroxypropylcellulose in the composition is from 5 10 to 30%, preferably 20 to 30%, of the total weight thereof.
Suitable as component B) in the compositions are active ingredi-ents or mixtures of active ingredients which are thermally stable under the processing conditions.
Examples of suitable active ingredients according to the inven-tion are:
acebutolol, acetylcysteine, acetylsalicylic acid, aciclovir, 15 alprazolam, albumin, alfacalcidol, allantoin, allopurinol, ambroxol, amikacin, amiloride, aminoacetic acid, amiodarone, ami-triptyline, amlodipine, amoxicillin, ampicillin, ascorbic acid, aspartame, astemizole, atenolol, beclometasone, benserazide, benzalkonium hydroxide, benzocaine, benzoic acid, betametasone, 20 bezafibrate, biotin, biperiden, bisoprolol, bromazepan, bromhex-ine, bromocriptine, budesonide, bufexamac, buflomedil, buspirone;
caffeine, camphor, captopril, carbamazepine, carbidopa, carbopla-tin, ~-carotene and other carotenoids, cefachlor, cefalexin, cefa-droxil, cefazolin, cefixime, cefotaxime, ceftazidine, ceftriax-25 one, cefuroxime axetil, chloramphenicol, chlorhexidine, chlorphe-niramine, chlortalidone, choline, ciclosporin, cilastatin, cime-tidine, ciprofloxacin, cisapride, cisplatin, clarithromycin, cla-vulanic acid, clomipramine, clonazepam, clonidine, clotrimazole, clozapine, codeine, colestyramine, cromoglicic acid, cyanocobala-30 min, cyproterone desogestrel, dexamethasone, dexpanthenol dextro-methorphan, dextropropoxiphene, diazepam, diclofenac, digoxin, dihydrocodeine, dihydroergotamine, diltiazem, diphenhydramine, dipyridamole, dipyrone, disopyramide, domperidone, dopamine, en-alapril, ephedrine, epinephrine, ergocalciferol, ergotamine, ery-35 thromycin, estradiol, ethinylestradiol, etoposide, Eucalyptusglobulus, fam-otidine, felodipine, fenofibrate, fenoterol, fenta-nyl, flavin mononucleotide, fluconazole, flunarizine, fluoroura-cil, fluoxetine, flurbiprofen, furosemide, gemfibrozil, gentami-cin, Ginkgo biloba, glibenclamide, glipizide, Glycyrrhiza glabra, 40 guaifenesin, haloperidol, heparin, hyaluronic acid, hydrochloro-thiazide, hydrocodone, hydrocortisone, hydromorphon, ipratropium hydroxide, ibuprofen, imipenem, indomethacin, iohexol, iopamidol, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, keto-tifen, ketoconazole, ketoprofen, ketorolac, labetalol, lactulose, 45 lecithin, levocarnitine, levodopa, levoglutamide, levonorgestrel, levothyroxine, lidocaine, lipase, lisinopril, loperamide, loraze-pam, lovastatin, medroxyprogesterone, menthol, methotrexate, me-~05U/46'74~
thyldopa, methylprednisolone, metoclopramide, metoprolol, micona-zole, midazolam, minocycline, minoxidil, misoprostol, morphine, multivitamins and minerals, nystatin, N-methyl-ephedrine, nafti-drofuril, naproxen, neomycin, nicardipine, nicergoline, nicotina-5 mide, nicotine, nicotinic acid, nifedipine, nimodipine, nitrendi-pine, nizatidine, norethisterone, norfloxacin, norgestrel, nor-triptlyine, ofloxacin, omeprazole, ondansetron, pancreatin, pan-thenol, pantothenic acid, paracetamol, penicillin G, penicillin V, phenobarbital, pentoxifylline, phenylephrine, phenylpropanola-10 mine, phenytoin, piroxicam, polymyxin B, povidone-iodine, pravas-tatin, prazosin, prednisolone, propafenone, propranolol, pseudo-ephedrine, pyridoxine, quinidine, ramipril, ranitidine, reser-pine, retinol, riboflavin, rifampicin, rutoside, saccharin, sal-butamol, salcatonin, salicylic acid, selegiline, simvastatin, so-15 matotropin, sotalol, spironolactone, sucralfate, sulbactam, sul-famethoxazole, sulpiride, tamoxifen, tegafur, teprenone, terazo-sin, terbutaline, terfenadine, theophylline, thiamine, ticlopi-dine, timolol, tranexamic acid, tretinoin, triamcinolone aceto-nide, triamterene, trimethoprim, troxerutin, uracil, valproic 20 acid, vancomycin, verapamil, vitamin E, folinic acid, zidovudine.
Crop protection agents are also suitable as active ingredients.
25 The amount of active ingredient component B) in the complete com-position may vary within wide limits depending on the activity.
Thus, the content of B) can be from 0.1 to 90~ of the total weight of the composition.
30 The compositions according to the invention can furthermore con-tain as components C) conventional pharmaceutical ancillary sub-stances as long as they are thermally stable under the processing conditions, eg. fillers or extenders, lubricants, plasticizers, stabilizers, dyes or pigments, disintegrants, preservatives or 35 flavorings. Examples of suitable fillers are organic compounds such as lactose or mannitol or inorganic substances such as silica or silicates, oxides of magnesium, aluminium or titanium.
Fillers which are readily soluble in water, such as lactose or mannitol, are suitable, for example, for producing compositions 40 with an increased rate of release of active ingredient.
The content of fillers in the composition depends on the dosage of active ingredient. In the case of active ingredients with low dosage, it is possible according to the invention to achieve, by 45 higher filler contents, a hlgher tablet weight without adversely affecting the melt processability. In the case of active ingredi-ents requiring very low doses, the amount of filler can be up to about 90~ by weight.
Further pharmaceutical ancillary substances which can be used are 5 flow regulators such as mono-, di- and triglycerides of long-chain fatty acids such as C12-, C14-, C16- and C1g fatty acids or waxes such as carnauba wax, in the conventional amounts.
Examples of plasticizers which may be mentioned are besides low 10 molecular weight polyalkylene oxides such as polyethylene glycol, polypropylene glycol and polyethylene/propylene glycol, also polyhydric alcohols such as propylene glycol, glycerol, pentaery-thritol and sorbitol, and sodium diethyl sulfosuccinate, glycerol mono-, di- and triacetate, and polyethylene glycol stearate. In 15 these cases, the amount of plasticizer is about 0.5 to 15, pre-ferably 0.5 to 5, % by weight.
Examples of lubricants which may be mentioned are stearates of aluminum or calcium, and talc and silicones, the amount thereof 20 being about 0.1 to 5, preferably 0.1 to 3, ~ by weight.
Examples of stabilizers which may be mentioned are light stabi-lizers, antioxidants, radical traps and stabilizers against microbial attack, all of which can be used in conventional 25 amounts.
In order to produce the compositions according to the invention, the active ingredient component can be either melted directly in the form of a physical mixture with the polymer A) or mixed with 30 the polymer melt which has already been produced.
Otherwise, the component is mixed with the melt in a conventional way in extruders, preferably in single or twin screw extruders at a temperature in the range from 50 to 200 C. The active ingredi-35 ent-containing polymer melt can be shaped to the compositions according to the invention for example by calenderinq the extrud-ate by the method described in EP-A 240 906, and by the proces-sing method disclosed in DE-A 38 30 335 by comminuting the extru-date with rotating knives into places of equal volume which are 40 still shapable. The cooled melt can also be processed to gran-ules.
It is possible to mix the ancillary substances into the melt of active ingredients and polymer AJ. It is furthermore possible to 45 incorporate the ancillary substances together with the active ingredient into the polymer melt. It is additionally possible to melt mixtures of ancillary substances, the active ingredient and the polymer A) directly. It is generally customary to melt a physical mixture of ancillary substances, active ingredients and polymers together.
5 The compositions according to the invention are used as drugs in the form of tablets or granules or employed as pellets in cap-sules.
If required, the solid pharmaceutical form can also be provided 10 with a conventional coating to improve the appearance and/or taste (coated tablet) or to reduce the rate of release of active ingredient.
The present invention makes it possible to produce in a simple 15 manner solid active ingredient compositions by melt extrusion, it being possible owing to the use of a specific polymer component to keep the polymer content low without adversely affecting the melt processability of the composition. It is possible in this way for a large part of the formulation to consist of active 20 ingredient and low-cost ancillary substances. This makes it pos-sible for solid drug forms to be produced at particularly reason-able cost. Particularly in the case of active ingredients requir-ing low doses it is possible according to the invention to pro-duce drugs of sizes which are easily handled by melt extrusion of 25 the compositions without the need to use a larger content of the comparatively high-cost polymer.
Example 1 30 8.0 kg of ambasilide (INN) are extruded with 2.0 kg of a hydroxy-propylcellulose with a degree of substitution of 3.0-4.4 and a DIN 53735 melt viscosity of 0.076 g/10 min in a twin screw extruder (ZSK-40 from ~erner + Pfleiderer, Stuttgart) under the following conditions:
Shot 1: 90 C
Shot 2: 120 C
Shot 3: 110 C
Shot 4: 110 C
40 Head: 120 C
Dies: 120 C
The throughput was 20 kg/h (weigh feeders). The hard homogeneous melt was directly compressed to tablets weighing 500 mg in a 45 molding calender located in front of the extruder head.
Example 2-The release of the active ingredient from the tablets from theexample was investigated by the USP XXI paddle method under the 5 following conditions:
- stirrer speed 75 rpm - release medium simulated gastric fluid (USP) pH 1.0 - temperature 37 C
10 - determination of active ingredient content in the release me-dium by W spectroscopy Measured active ingredient release:
Time [min] Active ingredient release (in [~]) O O
9.0 2030 13.6 17.5 21.1 270 60.0
The invention furthermore relates to a process for producing com-positions of this type and to drug forms from these compositions.
20 Melt extrusion and its use in pharmaceutical technology is gener-ally known.
US-A 4 801 460 describes the production of solid drug forms by melt extrusion of mixtures of active ingredient and thermoplastic 25 N-vinylpyrrolidone polymers.
JP-A 58-79915 and JP-A 58-192817 disclose the production of rod-shaped drug forms by melt extrusion of water-soluble polymers such as hydroxypropylcellulose (HPC) or mixtures of HPC with 30 other polymers.
EP-A 596 203 describes active ingredient-containing compositions which are obtained by mixing the active ingredient with a water-soluble melt of two polymers which differ in viscosity, for exam-35 ple polymer mixtures of hydroxypropylcellulose and hydroxypropyl-methylcellulose.
Active ingredient compositions disclosed to date usually have relatively high polymer contents. Although high polymer contents 40 result in good processability, the lower active ingredient con-tents which inevitably result therefrom, that is to say a low dose of active ingredient with a high tablet weight, may make the entire production process uneconomic.
45 If, for example, the active ingredient content in a tablet is originally 40% by weight, for the same dosage the tablet weight could be halved when the active ingredient content is doubled.
Thus, for a given extruder melt output, the production capacity of the extruder could be doubled.
On the other hand, in the case of active ingredients requiring a 5 low dose, a high active ingredient content would lead to drug forms whose total weight would be so low that it would be diffi-cult to handle such a small drug form. However, in such cases, it would be just as worthwhile to limit the content of the rela-tively high-cost polymers. In order for the weight of the drug 10 forms not to be less than the reasonable minimum, it would be worthwhile to replace part of the more costly polymer component by low-cost, not necessarily meltable ancillary substances.
It is an object of the present invention to find compositions 15 which have a low polymer content while permitting melt processing of the composition so that the content of active ingredient or active ingredient and low-cost ancillary substances in the com-position can be at a maximum.
20 We have found that this object is achieved by the compositions defined at the outset, and by a process for producing them, and the use thereof.
The component A) used according to the invention is a water-solu-25 ble thermoplastic hydroxypropylcellulose which preferably has a molar degree of substitution of from 3.0 to 4.4. "Molar degree of substitution" refers to the average number of moles of propylene oxide which have reacted per glucose unit in the cellulose.
30 The hydroxypropylcellulose can have melt viscosities measured by the DIN 53735 method in the range from 0.075 to 54.8 g/10 min.
The molecular weight of the hydroxypropylcellulose can vary with-in wide limits depending on whether slower or faster release of 35 active ingredient is desired. Hydroxypropylcellulose with molecu-lar weights in the range from 200,000 to 1,500,000 is suitable in particular for producing drug forms in which 510w release of act-ive ingredients is desired, since the polymers of higher molecu-lar weight dissolve less well, and only with swelling, in water.
If, however, it is intended to produce drug forms with faster release of active ingredient, it is advisable to use polymers of lower molecular weight which are readily soluble in water, it be-ing possible in this case to use hydroxypropylcellulose with a 45 molecular weight of from 60,000 to 200,000, preferably 60,000 to 100, 000.
The preparation of the hydroxypropylcellulose used according to the invention is generally known.
The content of hydroxypropylcellulose in the composition is from 5 10 to 30%, preferably 20 to 30%, of the total weight thereof.
Suitable as component B) in the compositions are active ingredi-ents or mixtures of active ingredients which are thermally stable under the processing conditions.
Examples of suitable active ingredients according to the inven-tion are:
acebutolol, acetylcysteine, acetylsalicylic acid, aciclovir, 15 alprazolam, albumin, alfacalcidol, allantoin, allopurinol, ambroxol, amikacin, amiloride, aminoacetic acid, amiodarone, ami-triptyline, amlodipine, amoxicillin, ampicillin, ascorbic acid, aspartame, astemizole, atenolol, beclometasone, benserazide, benzalkonium hydroxide, benzocaine, benzoic acid, betametasone, 20 bezafibrate, biotin, biperiden, bisoprolol, bromazepan, bromhex-ine, bromocriptine, budesonide, bufexamac, buflomedil, buspirone;
caffeine, camphor, captopril, carbamazepine, carbidopa, carbopla-tin, ~-carotene and other carotenoids, cefachlor, cefalexin, cefa-droxil, cefazolin, cefixime, cefotaxime, ceftazidine, ceftriax-25 one, cefuroxime axetil, chloramphenicol, chlorhexidine, chlorphe-niramine, chlortalidone, choline, ciclosporin, cilastatin, cime-tidine, ciprofloxacin, cisapride, cisplatin, clarithromycin, cla-vulanic acid, clomipramine, clonazepam, clonidine, clotrimazole, clozapine, codeine, colestyramine, cromoglicic acid, cyanocobala-30 min, cyproterone desogestrel, dexamethasone, dexpanthenol dextro-methorphan, dextropropoxiphene, diazepam, diclofenac, digoxin, dihydrocodeine, dihydroergotamine, diltiazem, diphenhydramine, dipyridamole, dipyrone, disopyramide, domperidone, dopamine, en-alapril, ephedrine, epinephrine, ergocalciferol, ergotamine, ery-35 thromycin, estradiol, ethinylestradiol, etoposide, Eucalyptusglobulus, fam-otidine, felodipine, fenofibrate, fenoterol, fenta-nyl, flavin mononucleotide, fluconazole, flunarizine, fluoroura-cil, fluoxetine, flurbiprofen, furosemide, gemfibrozil, gentami-cin, Ginkgo biloba, glibenclamide, glipizide, Glycyrrhiza glabra, 40 guaifenesin, haloperidol, heparin, hyaluronic acid, hydrochloro-thiazide, hydrocodone, hydrocortisone, hydromorphon, ipratropium hydroxide, ibuprofen, imipenem, indomethacin, iohexol, iopamidol, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, keto-tifen, ketoconazole, ketoprofen, ketorolac, labetalol, lactulose, 45 lecithin, levocarnitine, levodopa, levoglutamide, levonorgestrel, levothyroxine, lidocaine, lipase, lisinopril, loperamide, loraze-pam, lovastatin, medroxyprogesterone, menthol, methotrexate, me-~05U/46'74~
thyldopa, methylprednisolone, metoclopramide, metoprolol, micona-zole, midazolam, minocycline, minoxidil, misoprostol, morphine, multivitamins and minerals, nystatin, N-methyl-ephedrine, nafti-drofuril, naproxen, neomycin, nicardipine, nicergoline, nicotina-5 mide, nicotine, nicotinic acid, nifedipine, nimodipine, nitrendi-pine, nizatidine, norethisterone, norfloxacin, norgestrel, nor-triptlyine, ofloxacin, omeprazole, ondansetron, pancreatin, pan-thenol, pantothenic acid, paracetamol, penicillin G, penicillin V, phenobarbital, pentoxifylline, phenylephrine, phenylpropanola-10 mine, phenytoin, piroxicam, polymyxin B, povidone-iodine, pravas-tatin, prazosin, prednisolone, propafenone, propranolol, pseudo-ephedrine, pyridoxine, quinidine, ramipril, ranitidine, reser-pine, retinol, riboflavin, rifampicin, rutoside, saccharin, sal-butamol, salcatonin, salicylic acid, selegiline, simvastatin, so-15 matotropin, sotalol, spironolactone, sucralfate, sulbactam, sul-famethoxazole, sulpiride, tamoxifen, tegafur, teprenone, terazo-sin, terbutaline, terfenadine, theophylline, thiamine, ticlopi-dine, timolol, tranexamic acid, tretinoin, triamcinolone aceto-nide, triamterene, trimethoprim, troxerutin, uracil, valproic 20 acid, vancomycin, verapamil, vitamin E, folinic acid, zidovudine.
Crop protection agents are also suitable as active ingredients.
25 The amount of active ingredient component B) in the complete com-position may vary within wide limits depending on the activity.
Thus, the content of B) can be from 0.1 to 90~ of the total weight of the composition.
30 The compositions according to the invention can furthermore con-tain as components C) conventional pharmaceutical ancillary sub-stances as long as they are thermally stable under the processing conditions, eg. fillers or extenders, lubricants, plasticizers, stabilizers, dyes or pigments, disintegrants, preservatives or 35 flavorings. Examples of suitable fillers are organic compounds such as lactose or mannitol or inorganic substances such as silica or silicates, oxides of magnesium, aluminium or titanium.
Fillers which are readily soluble in water, such as lactose or mannitol, are suitable, for example, for producing compositions 40 with an increased rate of release of active ingredient.
The content of fillers in the composition depends on the dosage of active ingredient. In the case of active ingredients with low dosage, it is possible according to the invention to achieve, by 45 higher filler contents, a hlgher tablet weight without adversely affecting the melt processability. In the case of active ingredi-ents requiring very low doses, the amount of filler can be up to about 90~ by weight.
Further pharmaceutical ancillary substances which can be used are 5 flow regulators such as mono-, di- and triglycerides of long-chain fatty acids such as C12-, C14-, C16- and C1g fatty acids or waxes such as carnauba wax, in the conventional amounts.
Examples of plasticizers which may be mentioned are besides low 10 molecular weight polyalkylene oxides such as polyethylene glycol, polypropylene glycol and polyethylene/propylene glycol, also polyhydric alcohols such as propylene glycol, glycerol, pentaery-thritol and sorbitol, and sodium diethyl sulfosuccinate, glycerol mono-, di- and triacetate, and polyethylene glycol stearate. In 15 these cases, the amount of plasticizer is about 0.5 to 15, pre-ferably 0.5 to 5, % by weight.
Examples of lubricants which may be mentioned are stearates of aluminum or calcium, and talc and silicones, the amount thereof 20 being about 0.1 to 5, preferably 0.1 to 3, ~ by weight.
Examples of stabilizers which may be mentioned are light stabi-lizers, antioxidants, radical traps and stabilizers against microbial attack, all of which can be used in conventional 25 amounts.
In order to produce the compositions according to the invention, the active ingredient component can be either melted directly in the form of a physical mixture with the polymer A) or mixed with 30 the polymer melt which has already been produced.
Otherwise, the component is mixed with the melt in a conventional way in extruders, preferably in single or twin screw extruders at a temperature in the range from 50 to 200 C. The active ingredi-35 ent-containing polymer melt can be shaped to the compositions according to the invention for example by calenderinq the extrud-ate by the method described in EP-A 240 906, and by the proces-sing method disclosed in DE-A 38 30 335 by comminuting the extru-date with rotating knives into places of equal volume which are 40 still shapable. The cooled melt can also be processed to gran-ules.
It is possible to mix the ancillary substances into the melt of active ingredients and polymer AJ. It is furthermore possible to 45 incorporate the ancillary substances together with the active ingredient into the polymer melt. It is additionally possible to melt mixtures of ancillary substances, the active ingredient and the polymer A) directly. It is generally customary to melt a physical mixture of ancillary substances, active ingredients and polymers together.
5 The compositions according to the invention are used as drugs in the form of tablets or granules or employed as pellets in cap-sules.
If required, the solid pharmaceutical form can also be provided 10 with a conventional coating to improve the appearance and/or taste (coated tablet) or to reduce the rate of release of active ingredient.
The present invention makes it possible to produce in a simple 15 manner solid active ingredient compositions by melt extrusion, it being possible owing to the use of a specific polymer component to keep the polymer content low without adversely affecting the melt processability of the composition. It is possible in this way for a large part of the formulation to consist of active 20 ingredient and low-cost ancillary substances. This makes it pos-sible for solid drug forms to be produced at particularly reason-able cost. Particularly in the case of active ingredients requir-ing low doses it is possible according to the invention to pro-duce drugs of sizes which are easily handled by melt extrusion of 25 the compositions without the need to use a larger content of the comparatively high-cost polymer.
Example 1 30 8.0 kg of ambasilide (INN) are extruded with 2.0 kg of a hydroxy-propylcellulose with a degree of substitution of 3.0-4.4 and a DIN 53735 melt viscosity of 0.076 g/10 min in a twin screw extruder (ZSK-40 from ~erner + Pfleiderer, Stuttgart) under the following conditions:
Shot 1: 90 C
Shot 2: 120 C
Shot 3: 110 C
Shot 4: 110 C
40 Head: 120 C
Dies: 120 C
The throughput was 20 kg/h (weigh feeders). The hard homogeneous melt was directly compressed to tablets weighing 500 mg in a 45 molding calender located in front of the extruder head.
Example 2-The release of the active ingredient from the tablets from theexample was investigated by the USP XXI paddle method under the 5 following conditions:
- stirrer speed 75 rpm - release medium simulated gastric fluid (USP) pH 1.0 - temperature 37 C
10 - determination of active ingredient content in the release me-dium by W spectroscopy Measured active ingredient release:
Time [min] Active ingredient release (in [~]) O O
9.0 2030 13.6 17.5 21.1 270 60.0
Claims (6)
1. An active ingredient-containing composition obtainable by melt extrusion of a mixture of A) a water-soluble thermoplastic hydroxypropylcellulose, B) one or more active ingredients and C) if required conventional pharmaceutical ancillary substances, where the content of A) is from 10 to 30% of the total weight of the mixture.
2. A composition as claimed in claim 1, containing hydroxypropylcellulose with a molar degree of substitution of from 3.0 to 4.4
3. A process for producing an active ingredient-containing composition as claimed in claim 1 or 2, which comprises processing a mixture of A) a water-soluble thermoplastic hydroxypropylcellulose, B) one or more active ingredients and C) if required conventional pharmaceutical ancillary substances, where the content of A) is from 10 to 30% of the total weight of the mixture, to a melt and further processing with shaping of particles.
4. The use of the compositions as claimed in claim 1 or 2 for the production of drugs.
5. A solid drug form from the compositions as claimed in claim 1 or 2.
6. The use of the compositions as claimed in claim 1 or 2 for food supplementation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19504831.8 | 1995-02-14 | ||
| DE19504831A DE19504831A1 (en) | 1995-02-14 | 1995-02-14 | Solid active substance preparations containing hydroxypropyl cellulose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2211671A1 true CA2211671A1 (en) | 1996-08-22 |
Family
ID=7753889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002211671A Abandoned CA2211671A1 (en) | 1995-02-14 | 1996-02-01 | Solid active ingredient compositions containing hydroxypropylcellulose |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0809487A1 (en) |
| JP (1) | JPH11501618A (en) |
| CN (1) | CN1174502A (en) |
| AU (1) | AU4717096A (en) |
| CA (1) | CA2211671A1 (en) |
| DE (1) | DE19504831A1 (en) |
| IL (1) | IL117050A0 (en) |
| WO (1) | WO1996025149A1 (en) |
| ZA (1) | ZA961138B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060385A2 (en) | 2001-01-30 | 2002-08-08 | Smithkline Beecham Plc. | Pharmaceutical formulation |
| WO2005009380A2 (en) | 2003-07-21 | 2005-02-03 | Smith Kline Beecham P.L.C. | Pharmaceutical formulations |
| WO2009087483A2 (en) | 2007-11-08 | 2009-07-16 | Glaxo Group Limited | Pharmaceutical formulations |
| US7842308B2 (en) | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
| US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
| US8147871B2 (en) | 2004-03-12 | 2012-04-03 | Capsugel Belgium Bvba | Pharmaceutical formulations |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536387A1 (en) * | 1995-09-29 | 1997-04-03 | Basf Ag | Process for the preparation of vitamin-containing solid preparations |
| DE19710009A1 (en) * | 1997-03-12 | 1998-09-24 | Knoll Ag | Multi-phase preparation forms containing active ingredients |
| IT1298574B1 (en) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF POLYMER-BASED MICROPARTICLES OBTAINED BY EXTRUSION AND SPHERONIZATION |
| US6787157B1 (en) | 1998-03-10 | 2004-09-07 | Abbott Laboratories | Multiphase active ingredient-containing formulations |
| DE19842753A1 (en) | 1998-09-18 | 2000-03-23 | Bayer Ag | Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose |
| DE19934610A1 (en) * | 1999-07-23 | 2001-01-25 | Bayer Ag | Rapid-release extrudates containing low viscosity hydroxypropylcellulose, useful for formulating plant protecting agents and oral pharmaceutical and veterinary compositions |
| JP4310605B2 (en) * | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | Pharmaceutical composition |
| NZ562304A (en) * | 2005-05-10 | 2010-06-25 | Novartis Ag | Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride |
| CN100448432C (en) * | 2006-10-26 | 2009-01-07 | 徐竹青 | Method for preparing nimodipine dispersible tablet with high dissolution |
| MX358650B (en) | 2011-03-21 | 2018-08-30 | Boehringer Ingelheim Int | Solid ambroxol-containing preparation. |
| WO2018219801A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Immediate-release extrudates |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769029A (en) * | 1971-05-26 | 1973-10-30 | Hercules Inc | Method of making a thermoplastic food product |
| US4014675A (en) * | 1974-12-05 | 1977-03-29 | Hercules Incorporated | Fertilizer stick |
| JPS5879915A (en) * | 1981-11-09 | 1983-05-13 | Nippon Soda Co Ltd | Preparation of rod-shaped drug |
| JPS58192817A (en) * | 1982-05-06 | 1983-11-10 | Nippon Soda Co Ltd | Production of stick-like drug preparation |
| JPH03145418A (en) * | 1989-10-27 | 1991-06-20 | Sumitomo Pharmaceut Co Ltd | Sustained release preparation of basic drug hydrochloride |
| DE4226753A1 (en) * | 1992-08-13 | 1994-02-17 | Basf Ag | Preparations containing active substances in the form of solid particles |
| AU679937B2 (en) * | 1992-11-18 | 1997-07-17 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
-
1995
- 1995-02-14 DE DE19504831A patent/DE19504831A1/en not_active Withdrawn
-
1996
- 1996-02-01 JP JP8524616A patent/JPH11501618A/en active Pending
- 1996-02-01 AU AU47170/96A patent/AU4717096A/en not_active Abandoned
- 1996-02-01 EP EP96902968A patent/EP0809487A1/en not_active Withdrawn
- 1996-02-01 CN CN96191927A patent/CN1174502A/en active Pending
- 1996-02-01 WO PCT/EP1996/000418 patent/WO1996025149A1/en not_active Application Discontinuation
- 1996-02-01 CA CA002211671A patent/CA2211671A1/en not_active Abandoned
- 1996-02-06 IL IL11705096A patent/IL117050A0/en unknown
- 1996-02-13 ZA ZA9601138A patent/ZA961138B/en unknown
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060385A2 (en) | 2001-01-30 | 2002-08-08 | Smithkline Beecham Plc. | Pharmaceutical formulation |
| WO2002060384A2 (en) | 2001-01-30 | 2002-08-08 | Smithkline Beecham Plc. | Pharmaceutical formulation |
| US7842308B2 (en) | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
| US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
| EP2366383A2 (en) | 2001-01-30 | 2011-09-21 | Pfizer Inc. | Pharmaceutical formulation |
| EP2366382A2 (en) | 2001-01-30 | 2011-09-21 | Pfizer Inc. | Pharmaceutical formulation |
| EP2366384A2 (en) | 2001-01-30 | 2011-09-21 | Pfizer Inc. | Pharmaceutical formulation |
| US8361498B2 (en) | 2001-01-30 | 2013-01-29 | Capsugel Belgium Nv | Pharmaceutical formulation |
| WO2005009380A2 (en) | 2003-07-21 | 2005-02-03 | Smith Kline Beecham P.L.C. | Pharmaceutical formulations |
| US8673350B2 (en) | 2003-07-21 | 2014-03-18 | Capsugel Belgium Nv | Pharmaceutical formulations |
| US8147871B2 (en) | 2004-03-12 | 2012-04-03 | Capsugel Belgium Bvba | Pharmaceutical formulations |
| WO2009087483A2 (en) | 2007-11-08 | 2009-07-16 | Glaxo Group Limited | Pharmaceutical formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11501618A (en) | 1999-02-09 |
| CN1174502A (en) | 1998-02-25 |
| EP0809487A1 (en) | 1997-12-03 |
| DE19504831A1 (en) | 1996-09-05 |
| ZA961138B (en) | 1997-08-13 |
| IL117050A0 (en) | 1996-06-18 |
| WO1996025149A1 (en) | 1996-08-22 |
| AU4717096A (en) | 1996-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2211033C (en) | Solid active compound preparations | |
| CA2230950C (en) | Solid drug forms obtainable by extrusion of an isomalt-containing polymer/active ingredient melt | |
| CA2229650C (en) | Multiphase active ingredient-containing formulations | |
| US6488939B1 (en) | Cleavable solid dosage forms and method for the production thereof | |
| AU699971B2 (en) | The production of divisible tablets | |
| US6528089B1 (en) | Method for producing solid dosing forms | |
| CA2211671A1 (en) | Solid active ingredient compositions containing hydroxypropylcellulose | |
| US7419685B2 (en) | Process for producing solid dosage forms | |
| CA2367020C (en) | Method for producing solid dosage forms containing cyclodextrin | |
| US6284803B1 (en) | Solid dosage form with polymeric binder | |
| CA2209943A1 (en) | The production of solid drug forms | |
| US20100048760A1 (en) | Rapidly dispersable, particulate film-coating composition based on polyvinyl alcohol-polyether graft copolymers | |
| US6787157B1 (en) | Multiphase active ingredient-containing formulations | |
| ZA200503636B (en) | Method for producing solid galentic formulations using a crosslinked non-thermoplastic carrier | |
| US20180185287A1 (en) | Formulation Obtained from a Powder Mixture Comprising an Inorganic Pigment | |
| JPH11269098A (en) | Production of solid dosage form | |
| WO2007064397A2 (en) | Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability | |
| CA2232357A1 (en) | A process for producing solid drug forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |